GlassScriptPhysician profile
Shervin Shafa
NPI 1922254051
$13,300.90
in general payments reported to CMS, 2019-2025
11 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,996 · 2020: $119 · 2021: $1,655 · 2022: $1,600 · 2023: $304 · 2024: $4,742 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,850 · Food and Beverage: $1,141 · Travel and Lodging: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,850.00 |
| Food and Beverage | $1,141.12 |
| Travel and Lodging | $940.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $9,392.62 | 2021-2025 | Pentax Medical, C2 Cryoballoon, Inspira |
| Endogastric Solutions, INC | $1,916.25 | 2019-2020 | |
| Boston Scientific Corporation | $1,396.61 | 2023-2025 | Overstitch Endoscopic Suturing System, Resolution 360 Ultra Clip, Orise |
| Merit Medical Systems INC | $240.65 | 2025 | Esophyx |
| Genzyme Corporation | $130.00 | 2023 | |
| Pfizer INC. | $91.60 | 2019 | |
| Abbvie INC. | $84.66 | 2019 | |
| Celgene Corporation | $20.56 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $18.25 | 2019 | |
| Ambu INC. | $9.70 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shervin Shafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.